17 results on '"Cummings, F."'
Search Results
2. The effects of an integrated education programme on the management of diabetic ketoacidosis
- Author
-
Thompson, C J, primary, Cummings, F, additional, Jung, R T, additional, and Newton, R W, additional
- Published
- 1995
- Full Text
- View/download PDF
3. Abnormal Insulin Treatment Behaviour: a Major Cause of Ketoacidosis in the Young Adult
- Author
-
Thompson, C. J., primary, Cummings, F., additional, Chalmers, J., additional, and Newton, R. W., additional
- Published
- 1995
- Full Text
- View/download PDF
4. Evaluation of cell‐mediated reactivity and serum blocking factors in melanoma patients on chemotherapy
- Author
-
Cummings, F. J., primary, Heppner, Gloria H., additional, Calabresi, Paul, additional, Byrne, Michael, additional, and Stolbach, Leo, additional
- Published
- 1975
- Full Text
- View/download PDF
5. Successful therapy of crystalcryoglobulinemia: A case report
- Author
-
Cummings, F. J., primary, Park, C. H., additional, Bogaars, H. A., additional, Kalderon, A. E., additional, Melnicoff, I., additional, Kaplan, S. R., additional, Diamond, I., additional, and Calabresi, P., additional
- Published
- 1979
- Full Text
- View/download PDF
6. Clinical, pharmacologic, and immunologic effects of 2'-deoxycoformycin
- Author
-
Cummings, F J, primary, Crabtree, G W, additional, Wiemann, M C, additional, Spremulli, E N, additional, Parks, R E, additional, and Calabresi, Paul, additional
- Published
- 1988
- Full Text
- View/download PDF
7. Cell‐mediated and serum blocking reactivity to tumor antigens in patients with malignant melanoma
- Author
-
Heppner, G. H., primary, Stolbach, L., additional, Byrne, M., additional, Cummings, F. J., additional, McDonough, E., additional, and Calabresi, P., additional
- Published
- 1973
- Full Text
- View/download PDF
8. A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone.
- Author
-
Akerley W, Butera J, Wehbe T, Noto R, Stein B, Safran H, Cummings F, Sambandam S, Maynard J, Di Rienzo G, and Leone L
- Subjects
- Administration, Oral, Aged, Aged, 80 and over, Antineoplastic Agents, Hormonal administration & dosage, Antineoplastic Agents, Phytogenic administration & dosage, Carcinoma pathology, Combined Modality Therapy, Estramustine administration & dosage, Humans, Infusions, Intravenous, Male, Middle Aged, Palliative Care, Prostate-Specific Antigen blood, Prostatic Neoplasms pathology, Strontium Radioisotopes therapeutic use, Treatment Outcome, Vinblastine administration & dosage, Antineoplastic Agents, Hormonal pharmacology, Antineoplastic Agents, Phytogenic pharmacology, Carcinoma drug therapy, Carcinoma radiotherapy, Estramustine pharmacology, Prostatic Neoplasms drug therapy, Prostatic Neoplasms radiotherapy, Vinblastine pharmacology
- Abstract
Background: Estramustine phosphate (EMP) and vinblastine have radiosensitizing properties and significant activity against hormone refractory prostate carcinoma. Strontium-89 is a palliative agent that acts as a selective radiation source for bone metastasis. The combination of EMP, vinblastine, and strontium-89 was developed to exploit the potential for radiosynergy. PATIENTS AND METHODS Forty-four patients at the Brown Oncology Group affiliated hospitals were treated with oral EMP 600 mg/m2 daily on Weeks 1-4 and 7-10, vinblastine 4 mg/m2 intravenously once each week on Weeks 1-4 and 7-10, and strontium-89 2.2 MBq/kg on Day 1. Courses were repeated every 12 weeks. Response assessment was based on a change in the serum prostate specific antigen (PSA) levels, correlated with change in measurable disease and bone scan appearance., Results: A greater than or equal to 50% decline in PSA for at least 6 weeks was observed in 21 patients (48%, 95% confidence interval, 33-62%). Median duration of response was 23 weeks (range, 6-70.8 weeks). The median survival was 13 months with 1- and 2-year survival rates of 55% and 25%, respectively. After completion of protocol therapy, a retrospective review showed that only nine patients received subsequent palliative external beam radiation after progression., Conclusions: The addition of strontium-89 to the regimen of EMP and vinblastine can be delivered safely and in repeated doses, provides effective palliation, and may decrease the need for future radiation therapy. A randomized trial is necessary to quantify these effects., (Copyright 2002 American Cancer Society.)
- Published
- 2002
- Full Text
- View/download PDF
9. Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen.
- Author
-
Gale KE, Andersen JW, Tormey DC, Mansour EG, Davis TE, Horton J, Wolter JM, Smith TJ, and Cummings FJ
- Subjects
- Adrenalectomy, Female, Humans, Aminoglutethimide therapeutic use, Breast Neoplasms drug therapy, Tamoxifen therapeutic use
- Abstract
Background: Tamoxifen and aminoglutethimide are two hormone therapies reported to be effective palliative approaches for patients with metastatic breast cancer. The current trial was designed to evaluate their relative therapeutic effectiveness., Methods: Two hundred forty-nine postmenopausal women with advanced breast cancer were randomized in an Eastern Cooperative Oncology Group (ECOG) Phase III study to treatment with adrenalectomy, aminoglutethimide, or tamoxifen with crossover to alternate therapy if disease progressed. Adrenalectomy was dropped as a treatment after 2 years because of low patient accrual., Results: There were 216 evaluable patients entered in the study with 108 initially randomized to aminoglutethimide and 108 to receive tamoxifen therapy. The overall response rate for aminoglutethimide was 45%, and for tamoxifen it was 27%. One institution had a response rate of 60% with aminoglutethimide and only 4% with tamoxifen, whereas all of the other institutions combined had a response rate of 41% with aminoglutethimide and 34% with tamoxifen. Eighty-seven evaluable patients crossed over to the other drug (44 to aminoglutethimide and 43 to tamoxifen). There was a 36% response rate to aminoglutethimide and 19% to tamoxifen, with stable disease in 36% of both groups. The overall survival rates were identical. Toxicity was greater with aminoglutethimide (dermatitis) but was not life-threatening. Glucocorticoid support with either dexamethasone or hydrocortisone was acceptable., Conclusions: Both aminoglutethimide and tamoxifen produced responses in postmenopausal patients with breast cancer, and a significant number of crossover responses were observed. Of interest in this randomized study was the observation that one institution had a markedly different response rate on induction, reinforcing the need for multi-institution trials in Phase III studies.
- Published
- 1994
- Full Text
- View/download PDF
10. High-dose intravenous zidovudine with 5-fluorouracil and leucovorin. A phase I trial.
- Author
-
Posner MR, Darnowski JW, Weitberg AB, Dudley MN, Corvese D, Cummings FJ, Clark J, Murray C, Clendennin N, and Bigley J
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols pharmacokinetics, DNA Damage, DNA, Neoplasm drug effects, Dose-Response Relationship, Drug, Fluorouracil administration & dosage, Humans, Infusions, Intravenous, Leucovorin administration & dosage, Middle Aged, Zidovudine adverse effects, Zidovudine pharmacokinetics, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Neoplasms drug therapy, Zidovudine administration & dosage
- Abstract
Background: The inhibition of pyrimidine metabolism by 5-fluorouracil (5-FU) enhances the anti-cancer effects of zidovudine (formerly called AZT) in in vitro and in vivo model systems without additive toxicity. Zidovudine-induced DNA damage correlates with cytotoxicity., Methods: A Phase I trial of high-dose continuous-infusion intravenous zidovudine therapy in combination with 5-FU and leucovorin therapy was performed. Eighteen patients with advanced malignant tumors were treated with 43 courses of oral leucovorin (50 mg every 4 hours); continuous-infusion 5-FU (800 mg/M2/day) for 72 hours (3 days); and zidovudine, begun 24 hours after the start of 5-FU and leucovorin, for 48 hours, and terminating with the end of the 5-FU infusion. Zidovudine plasma levels and zidovudine-induced DNA damage were assessed., Results: Zidovudine administered in doses of 2-20 g/M2/day, added no obvious toxicity to the basic chemotherapeutic treatment with 5-FU and leucovorin but resulted in a dose-dependent biologic effect manifested by an increase in DNA strand breaks in peripheral blood cells. At doses greater than 15 g/M2/day, altered plasma kinetics of zidovudine were observed; plasma zidovudine levels increased dramatically in relation to the dose of zidovudine. Limitations in drug administration restricted administration of higher intravenous doses without achieving a maximally tolerated dose. No responses were seen in this heavily pretreated population., Conclusions: Based on the results of preclinical studies, plasma zidovudine levels greater than those achieved at the maximal dose (133 microns) are required for increased anti-cancer activity with 5-FU. Additional studies using a bolus or rapid infusion as a method of achieving higher peak levels are indicated.
- Published
- 1992
- Full Text
- View/download PDF
11. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
- Author
-
Tormey DC, Gray R, Gilchrist K, Grage T, Carbone PP, Wolter J, Woll JE, and Cummings FJ
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Breast Neoplasms mortality, Cyclophosphamide administration & dosage, Female, Fluorouracil administration & dosage, Humans, Menopause, Methotrexate administration & dosage, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Prednisone administration & dosage, Prevalence, Prognosis, Randomized Controlled Trials as Topic, Survival Analysis, Tamoxifen administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy
- Abstract
The current trial was designed to assess whether the addition of prednisone or prednisone + tamoxifen would enhance the therapeutic effectiveness of 1 year of adjuvant CMF therapy. Premenopausal women with ipsilateral axillary node-positive breast carcinoma and known estrogen receptor (ER) status were randomized to receive 1 year of postoperative treatment with 12 28-day cycles of cyclophosphamide, methotrexate, 5-fluorouracil (CMF), CMF plus prednisone (CMFP), or CMFP plus tamoxifen (CMFPT). There were 553 analyzed cases with 188 receiving CMF, 183 CMFP, and 182 CMFPT. The overall time to relapse (TTR) and survival comparisons between the regimens are not statistically different at a median follow-up time of 7.7 years. The major subgroups currently with a suggestive TTR difference are greater than 3N+ (CMFPT greater than CMF, P = 0.07) and estrogen receptor-negative (ER-) greater than 3N+ (CMFPT greater than CMF, P = 0.03). Patients receiving CMFPT appeared to have a superior survival to CMF in the ER- greater than 3N+ cohort (P = 0.02). The following patient characteristics were associated with a significantly longer TTR: decreasing nodal involvement or tumor size, positive ER status, age greater than or equal to 40 years, and decreasing obesity. The favorable effects of decreasing nodal involvement, positive ER status, age 40 years or greater, and decreasing obesity carried over to survival. Development of amenorrhea was also significantly associated with improved survival (P = 0.001). Toxicity was increased by the addition of prednisone to CMF and by the addition of tamoxifen to CMFP. Overall relapse patterns were similar among the three regimens. The results of the current trial do not currently suggest an overall therapeutic benefit for adding prednisone or only 1 year of tamoxifen to CMF adjuvant treatment.
- Published
- 1990
- Full Text
- View/download PDF
12. Phase II trials of Baker's antifol, bleomycin, CCNU, streptozotocin, tilorone, and 5-fluorodeoxyuridine plus arabinosyl cytosine in metastatic breast cancer.
- Author
-
Cummings FJ, Gelman R, Skeel RT, Kuperminc M, Israel L, Colsky J, and Tormey D
- Subjects
- Antineoplastic Agents adverse effects, Bleomycin administration & dosage, Breast Neoplasms mortality, Cytarabine administration & dosage, Drug Evaluation, Drug Therapy, Combination, Female, Floxuridine administration & dosage, Humans, Lomustine administration & dosage, Probability, Streptozocin administration & dosage, Tilorone administration & dosage, Triazines administration & dosage, Antineoplastic Agents administration & dosage, Breast Neoplasms drug therapy
- Abstract
A total of 202 patients with advanced breast cancer were entered into two prospectively randomized Phase II trials conducted by the Eastern Cooperative Oncology Group, in an effort to identify promising agents and combinations for previously treated cases. Patients in Study 1 received bleomycin, CCNU, or streptozotocin and those in Study 2 received tilorone, Baker's antifol, or a combination of 5-fluorodeoxyuridine plus arabinosyl cytosine. Partial responses were seen only with bleomycin, Baker's antifol, and 5-fluorodeoxyuridine plus arabinosyl cytosine. The median times to treatment failure ranged from 3.6 weeks to 5.7 weeks, and the median survival times, from 8 weeks to 25 weeks for tilorone and bleomycin, respectively. Toxic reactions was primarily hematologic and gastrointestinal, but skin, neurologic, respiratory, and renal abnormalities were noted in some treatment arms. The treatment schedules outlined and the toxic effects noted provide background information that might prove useful in designing complex new chemotherapeutic programs, since there is pharmacological rationale for incorporating some of the agents tested into present standard combination chemotherapy regimens.
- Published
- 1981
- Full Text
- View/download PDF
13. A phase I trial of continuous infusion cisplatin.
- Author
-
Posner MR, Ferrari L, Belliveau JF, Cummings FJ, Wiemann MC, O'Rourke A, Weitberg AB, and Calabresi P
- Subjects
- Adult, Aged, Cisplatin adverse effects, Cisplatin therapeutic use, Drug Evaluation, Female, Hematologic Diseases chemically induced, Humans, Infusions, Intravenous, Kidney Diseases chemically induced, Male, Middle Aged, Neoplasms pathology, Cisplatin administration & dosage, Neoplasms drug therapy
- Abstract
Treatment with continuous infusions of cisplatin results in increased filterable drug exposures as measured by the area under the curve (AUC) of nonprotein-bound plasma platinum levels. To determine the dose-limiting toxicity and optimal method of administration, 24 patients were treated with continuous infusions of cisplatin at a dose rate of 25 mg/M2/day in a limited Phase I trial. A total of 47 courses were given. Nine patients received 13 courses of 4 days duration, 19 received 29 courses of 5 days duration, and five received courses of 6 or 7 days duration. Dose-limiting toxicity was found to be leukopenia: 42% of patients receiving the 5-day treatment developed a nadir count of less than 3000 cells/mm3. Nausea and vomiting were easily controlled. Minimal nephrotoxicity occurred in five patients and was associated with daily volume expansion with 2 l of 0.9% NaCl solution in four patients. All other patients were given 3 l of daily volume expansion during treatment. Responses were seen in 6 of 22 evaluable patients (27%). It is concluded that continuous infusion cisplatin at a dose rate of 25 mg/M2/day can be given safely for 5 days as a single agent if concomitant volume expansion with at least 3 l of 0.9% NaCl solution is given daily. Phase III comparative trials with a conventional bolus and newer high-dose regimens for response and toxicity are indicated.
- Published
- 1987
- Full Text
- View/download PDF
14. Preoperative simultaneously administered cis-platinum plus radiation therapy for advanced squamous cell carcinoma of the head and neck.
- Author
-
Slotman GJ, Cummings FJ, Glicksman AR, Doolittle CL, and Leone LA
- Subjects
- Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell radiotherapy, Combined Modality Therapy, Drug Evaluation, Head and Neck Neoplasms mortality, Head and Neck Neoplasms radiotherapy, Humans, Neoplasm Staging, Radiotherapy Dosage, Time Factors, Carcinoma, Squamous Cell drug therapy, Cisplatin therapeutic use, Head and Neck Neoplasms drug therapy, Preoperative Care methods
- Abstract
Synchronously administered cis-platinum (cis-DDP) and radiation therapy have been used to treat unresectable squamous cell carcinomas of the head and neck. The purpose of this study was to evaluate the efficacy and tolerance of preoperative adjuvant cis-DDP plus radiation therapy in operable stage III and IV head and neck cancers. Radiation therapy (4,500 rad) was delivered in 180-rad daily fractions. Cis-DDP (20 mg/M2) was given before radiotherapy on days 1-4 and 21-24. Eighteen patients began therapy; 16 completed the combined regimen. Toxicity included stomatitis and WBC below 2,500/mm3. One patient died from therapy of a cerebrovascular accident. Sixteen patients (89%) achieved a complete or partial response to therapy. Complete responses were observed in 13 of 18 primary tumors (72%), and in all three patients with cervical lymphadenopathy. Complete responses were noted for lesions of the nasopharynx, oral cavity, pharynx, hypopharynx, and larynx, for all histologic grades of squamous cell carcinoma. Twelve patients underwent curative surgery. Site-related morbidity occurred in two patients (15%) and a third patient developed postoperative pneumonia. Five of 10 resected primary tumors with preoperative complete responses were pathologically negative for tumor. Concurrent bolus cis-DDP and radiation therapy are well-tolerated and result in impressive tumor reduction. Morbidity after subsequent curative surgery is low, and histologic complete responses are frequent.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1986
- Full Text
- View/download PDF
15. Ultrastructure of myeloma cells in a case with crystalcryoglobulinemia.
- Author
-
Kalderon AE, Bogaars HA, Diamond I, Cummings FJ, Kaplan SR, and Calabresi P
- Subjects
- Bone Marrow ultrastructure, Crystallization, Endoplasmic Reticulum ultrastructure, Extracellular Space ultrastructure, Golgi Apparatus ultrastructure, Humans, Immunoglobulin kappa-Chains, Male, Middle Aged, Multiple Myeloma metabolism, Cryoglobulins metabolism, Multiple Myeloma ultrastructure, Myeloma Proteins metabolism
- Abstract
The bone marrow of a patient with multiple myeloma of the IgG2 Kappa type with spontaneously crystallizing cryoglobulin was studied by electron microscopy. The ultrastructure of the myeloma cells disclosed the presence of a crystalline material in the cytoplasm within the rough endoplasmic reticulum (RER) as well as in extracisternal sites. The crystalline material was also seen extracellulary with a distinctly unique subunit structure. The tubular units measured 200 +/- A (SEM) externally with an internal diameter of 100 +/- A (SEM). The intracellular distribution did not indicate a characteristic organelle association usually observed in protein synthesizing cells. It is suggested, based on the present observations and the findings of others, that the crystalline material may represent polymerized protein synthesized by free ribosomes mostly in extracisternal locations, a pattern often seen in neoplastic plasma cells. Diffusion to extracisternal sites of precrystalline material through the membranes of the RER is a possible alternative mechanism.
- Published
- 1977
- Full Text
- View/download PDF
16. The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
- Author
-
Falkson G, Gelman RS, Tormey DC, Cummings FJ, Carbone PP, and Falkson HC
- Subjects
- Bone Neoplasms secondary, Breast Neoplasms pathology, Cyclophosphamide administration & dosage, Doxorubicin administration & dosage, Female, Fluorouracil administration & dosage, Hematologic Diseases chemically induced, Humans, Menopause, Neoplasm Metastasis, Neoplasm Recurrence, Local drug therapy, Prognosis, Skin Neoplasms secondary, Time Factors, Vomiting chemically induced, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy
- Abstract
Data on 162 women (90 premenopausal and 72 postmenopausal) with metastatic breast cancer randomized to receive cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF) on two Eastern Cooperative Oncology Group (ECOG) protocols were analyzed. Twenty-three percent had complete remission; 39% had partial remission; 28% had no change; and 3% had disease progression. Of those patients in whom receptors were known, response rates were 65% for estrogen (ER)-receptor positive and 70% for ER-negative patients. The median duration of response was 11.4 months. The median survival time from the start of CAF was 20.2 months. The response rate, time to treatment failure (TTF), and median survival time were superior in the premenopausal women. These differences ceased, however, to be statistically significant in logistic models. Factors significantly associated with longer TTF and longer survival were as follows: one or two organs with metastases (TTF, P less than 0.0001; survival, P less than 0.0001); dominant site other than soft tissue (TTF, P less than 0.0001; survival, P = 0.05); and an initial good performance status (TTF, P = 0.007; survival, P = 0.02). Patients with ER-positive disease had a significantly longer median survival time (P = 0.003).
- Published
- 1985
- Full Text
- View/download PDF
17. A human breast stromal sarcoma cell line with features of malignant cystosarcoma phyllodes.
- Author
-
Tibbetts LM, Poisson MH, Tibbetts LL, and Cummings FJ
- Subjects
- Aged, Animals, Breast Neoplasms ultrastructure, Cell Division, Cell Line, Culture Techniques methods, Female, Glycosaminoglycans analysis, Humans, Male, Mice, Mice, Nude, Microscopy, Electron, Neoplasm Transplantation, Phyllodes Tumor ultrastructure, Receptors, Estradiol analysis, Receptors, Progesterone analysis, Transplantation, Heterologous, Breast Neoplasms pathology, Phyllodes Tumor pathology
- Abstract
A cell line was established from a portion of a 25-cm stromal sarcoma of the left breast of a 65-year-old woman. The clinical course was rapid with tumor recurrence on the chest wall less than 1 month after mastectomy. Other cutaneous and abdominal metastases occurred shortly thereafter, and death followed within 3 months despite chemotherapy. The cultured cells, designated RW-972, produced large amounts of acid mucopolysaccharides (hyaluronic acid) and mimicked the aggressive growth characteristics seen in the patient. After injection into nude mice, the tumor grew rapidly and occasionally produced metastases. This unique cell line, RW-972, presumably derived from the stromal component of a human malignant cystosarcoma phyllodes, might be useful in studies of experimental therapy of this rare tumor type and of lobular stromal cells of breast. It may also be used to investigate hyaluronic acid production by tumor cells.
- Published
- 1988
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.